Clinical Oncology evaluations can include various molecular tests and the results can influence patient care. One example of an Oncology Molecular Diagnostic is mutation analysis for genes known to be confer a high risk of cancer such as BRCA1/2. Healthy patients found to carry this mutation benefit from increased screening and surveillance due to their increased risk of several cancers.
DATE: July 30, 2019TIME: 6:00am PT, 9:00am ET The current version of the EMA Guideline for the environmental risk assessment of human drugs was published in 2006. This guidance...
DATE: July 23, 2019TIME: 10:00am PDTThe tumor microenvironment is a complex network of different cell types and states that imparts distinct properties to the tumor and plays a signif...
Tumor heterogeneity is a hallmark of cancer and can have significant impact on identifying drivers, including those that may be therapeutically relevant. Although, the traditional sequencing...
Implementing precision genomic medicine in the pediatric acute care setting has several challenges. First, the diagnosis must be made quickly. Second, the determination of pathogenicity mus...
The practice of precision medicine utilizes advanced diagnostic tools to identify specific groups of patients on the basis of particular molecular characteristics, and guide their treatment w...
The long term goal of our collaborative effort is to bring precision medicine to the practice of veterinary oncology, using the wealth of genomic data gathered in human cancers as a roadmap....
Clopidogrel, an antiplatelet agent frequently used for secondary stroke prevention, is a prodrug that requires both sufficient intestinal absorption and hepatic modification to produce its ac...
This talk will review successful efforts at Washington University to employ novel reagents and informatics to the problem of rare allele detection. I will discuss a published bakeoff of in si...
The development of automated DNA sequencers utilizing Sanger sequencing and capillary electrophoresis made it possible to develop the first draft sequences of the human genome. The cost of do...
In this presentation, Dr. Kothari will provide an overview of the Precision Medicine Initiative from NIH and how NGS technologies have helped the researchers to look deep inside the human tra...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Recent advances in genomic technologies have revealed enormous complexities and uniqueness of human physiology. Although enormous efforts are being made to apply this knowledge to enhance the...
The NIH put Precision Medicine on the map as a revolutionary way to manage disease, delivering the right treatment, to the right patient, at the right time. But what does Precision Medicine r...
Most cancer therapies have highly variable activity from one patient to another, with only a fraction of patients’ cancers responding to a given treatment. In many types of cancer, comb...
It has been noted by many in the community that for Precision Medicine to become a transformative reality, the underlying DNA and RNA sequence data have to become more precise. In my talk, I...
Virtually all tumors are genetically heterogeneous, containing subclonal populations of cells that are defined by distinct mutations. Subclones can have unique phenotypes that influence disea...
Inherited disorders affect millions of people globally. These diseases significantly impact lives of patients and their families, and in addition, also results in substantial socio-economic i...
DATE: June 19, 2019TIME: 8:00am PDT, 11:00am EDT Approximately 80% of all cancers are known to be affected by both somatic mutations and copy number changes. Furthermore, r...
DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
Point-of-care testing (POCT) is diagnostic testing at the time and place of patient care in a physician’s office, an ambulance, a mobile clinic, at home or in hospital. Rapid POC testi...
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are d...
The exponential advents of advances in techniques and types of molecular diagnostic testing, and modifying strategies for these tests, are encouraging; but these evolutions simultaneously con...
DATE: July 30, 2019TIME: 6:00am PT, 9:00am ET The current version of the EMA Guideline for the environmental risk assessment of human drugs was published in 2006. This guidance...
DATE: July 23, 2019TIME: 10:00am PDTThe tumor microenvironment is a complex network of different cell types and states that imparts distinct properties to the tumor and plays a signif...
Tumor heterogeneity is a hallmark of cancer and can have significant impact on identifying drivers, including those that may be therapeutically relevant. Although, the traditional sequencing...
Implementing precision genomic medicine in the pediatric acute care setting has several challenges. First, the diagnosis must be made quickly. Second, the determination of pathogenicity mus...
The practice of precision medicine utilizes advanced diagnostic tools to identify specific groups of patients on the basis of particular molecular characteristics, and guide their treatment w...
The long term goal of our collaborative effort is to bring precision medicine to the practice of veterinary oncology, using the wealth of genomic data gathered in human cancers as a roadmap....
Clopidogrel, an antiplatelet agent frequently used for secondary stroke prevention, is a prodrug that requires both sufficient intestinal absorption and hepatic modification to produce its ac...
This talk will review successful efforts at Washington University to employ novel reagents and informatics to the problem of rare allele detection. I will discuss a published bakeoff of in si...
The development of automated DNA sequencers utilizing Sanger sequencing and capillary electrophoresis made it possible to develop the first draft sequences of the human genome. The cost of do...
In this presentation, Dr. Kothari will provide an overview of the Precision Medicine Initiative from NIH and how NGS technologies have helped the researchers to look deep inside the human tra...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Recent advances in genomic technologies have revealed enormous complexities and uniqueness of human physiology. Although enormous efforts are being made to apply this knowledge to enhance the...
The NIH put Precision Medicine on the map as a revolutionary way to manage disease, delivering the right treatment, to the right patient, at the right time. But what does Precision Medicine r...
Most cancer therapies have highly variable activity from one patient to another, with only a fraction of patients’ cancers responding to a given treatment. In many types of cancer, comb...
It has been noted by many in the community that for Precision Medicine to become a transformative reality, the underlying DNA and RNA sequence data have to become more precise. In my talk, I...
Virtually all tumors are genetically heterogeneous, containing subclonal populations of cells that are defined by distinct mutations. Subclones can have unique phenotypes that influence disea...
Inherited disorders affect millions of people globally. These diseases significantly impact lives of patients and their families, and in addition, also results in substantial socio-economic i...
DATE: June 19, 2019TIME: 8:00am PDT, 11:00am EDT Approximately 80% of all cancers are known to be affected by both somatic mutations and copy number changes. Furthermore, r...
DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
Point-of-care testing (POCT) is diagnostic testing at the time and place of patient care in a physician’s office, an ambulance, a mobile clinic, at home or in hospital. Rapid POC testi...
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are d...
The exponential advents of advances in techniques and types of molecular diagnostic testing, and modifying strategies for these tests, are encouraging; but these evolutions simultaneously con...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
